Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 34

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 34
---
 or design. We may be subject to infringement claims from our products. In addition, we may be subject to claims
by our lenders, claims for rent, and claims from our vendors on our accounts payable; and although we have been able to obtain understandings
with the foregoing and have informal forbearance agreements from those parties, one or more of them may elect to commence collection
proceedings which could result in judgments against us and have a significant negative impact on our operations

Currently there are no claims against us from
any third party.

<div align='center'>16</div>

Risks Relating to Operations in Israel

Our principal executive offices, most of our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including Israel’s multi-front war with terrorist groups in neigh boring countries, such as Hezbollah in Lebanon and Hamas in the Gaza Strip, and state actors such as Iran, and Israel’s response thereto

A significant portion of our R&D operations
is based in Israel. Recent escalations in regional conflicts have disrupted business activities and may continue to do so. We have developed
contingency plans, including the potential outsourcing of critical operations and establishing remote work protocols for key personnel.
However, prolonged disruptions could materially impact our ability to meet development milestones. Our technology development headquarters,
which houses substantially all of our research and development team, including researchers, and clinical and regulatory personnel are
located at our headquarters in Herzliya, Israel. Three employees are currently engaged in research and development activities. Our employees,
service providers, directors and officers are residents of Israel.

In October 2023, Hamas terrorists infiltrated
Israel’s border with the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel’s
security cabinet declared war against Hamas and a military campaign commenced in the Gaza Strip. The continuation of the conflict has
led to heightened security concerns, potential disruptions to business operations, and economic instability. There remains significant
uncertainty regarding the duration and escalation of the conflict, and further military actions, restrictions, or government-imposed
measures could adversely affect our operations and financial condition. Other regional hostilities, since October 7, 2023, have concurrently
become more pronounced. This includes and has included a northern front war between Israel and Hezbollah and continued conflict with
the Houthi Movement in Yemen as well as the direct conflict between Israel and